rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LNTH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lantheus reports Phase 3 trial results for Alzheimer’s tau imaging agent
      Nov 16Investing.comLNTH
      Lantheus Holdings Inc earnings beat by $0.42, revenue topped estimates
      Nov 5Investing.comLNTH
      Lantheus Holdings: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceLNTH
      ETFs Are Net Sellers of Lantheus (LNTH) on Oct. 22
      Oct 26Yahoo FinanceLNTH
      Lantheus receives FTC second request on Curium deal
      Oct 22Seeking AlphaLNTH
      ETFs Are Selling Lantheus (LNTH) on Oct. 19

      Nine ETFs sold $22.8 million of Lantheus stock on Monday, against three buyers.

      Oct 21Yahoo FinanceLNTH
      Update: Market Chatter: JPMorgan Leads, Jefferies Joins $4.25 Billion Financing for Lantheus Deal
      Oct 16Yahoo FinanceLNTH
      Market Chatter: JPMorgan Leads, Jefferies Joins $4.25 Billion Financing for Lantheus Deal
      Oct 15Yahoo FinanceLNTH
      Banks Vie for $4.25 Billion Debt Financing to Back Lantheus Deal
      Oct 15BloombergLNTH
      Lantheus doses first patient in prostate cancer imaging trial
      Sep 28Investing.comLNTH
      Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

      FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...

      Sep 26Yahoo FinanceLNTH
      Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

      Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

      Sep 23Yahoo FinanceLNTH
      FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors
      Sep 22Investing.comLNTH
      Lantheus Says Curium Resubmits Antitrust Filing for Merger

      Lantheus Holdings (LNTH) said Monday that Curium resubmitted its pre-merger notification, beginning

      Sep 22Yahoo FinanceLNTH
      Lantheus Says FDA Approves Cancer Drug
      Sep 22Yahoo FinanceLNTH
      Lantheus alpha therapy, CATX director, sells $131k in stock
      Sep 5Investing.comLNTH
      Lantheus Holdings sells $245,609 in Perspective Therapeutics stock
      Sep 2Investing.comLNTHCATX
      Curium acquisition of Lantheus backed by $5.375B of debt financing

      Committed debt financing supporting the previously announced acquisition of Lantheus Holdings by Curium includes a senior secured multicurrency revolving credit facility and a $4.25 billion senior secured term loan B facility, according to a regulatory filing. In addition, Curium Midco entered into a separate commitment letter for a $1.125 billion PIK facility. The TLB and revolver will be incurred as additional facilities under Curium BidCo’s existing credit agreement, with JPMorgan as administ

      Aug 26Yahoo FinanceLNTH

      This is the newest page. Registered accounts read further back.